Table I.
Patient demographic and clinical characteristics stratified by race
| Characteristic | All patients (n = 876) | Race |
P value | |||
|---|---|---|---|---|---|---|
| White (n = 694) | Black/African American (n = 111) | Asian (n = 48) | Other (n = 23) | |||
| Male sex | 521 (59.5) | 425 (61.2) | 49 (44.1) | 32 (66.7) | 15 (65.2) | .004 |
| Age, years | 65.0 (53.0-77.0) | 67.0 (56.0-78.0) | 55.0 (43.5-5.0) | 62.5 (45.8-70.5) | 57.0 (48.0-68.5) | <.001 |
| Hypertension | 552 (63.0) | 433 (62.4) | 78 (70.3) | 32 (66.7) | 9 (39.1) | .04 |
| Coronary artery disease | 217 (24.8) | 181 (26.1) | 20 (18.0) | 13 (27.1) | 3 (13.0) | .16 |
| Myocardial infarction | 79 (9.0) | 63 (9.1) | 10 (9.0) | 4 (8.3) | 2 (8.7) | 1.00 |
| Diabetes mellitus | 220 (25.1) | 167 (24.1) | 35 (31.5) | 9 (18.8) | 9 (39.1) | .10 |
| Peripheral vascular disease | 51 (5.8) | 45 (6.5) | 4 (3.6) | 0 (0) | 2 (8.7) | .14 |
| Ischemic stroke | 55 (6.3) | 42 (6.1) | 11 (9.9) | 1 (2.1) | 1 (4.4) | .28 |
| Transient ischemic attack | 49 (5.6) | 42 (6.1) | 5 (4.5) | 2 (4.1) | 0 (0) | .76 |
| Intracerebral hemorrhage | 13 (1.5) | 10 (1.4) | 2 (1.8) | 1 (2.1) | 0 (0) | .72 |
| Atrial fibrillation | 157 (17.9) | 139 (20.0) | 11 (9.9) | 5 (10.4) | 2 (8.7) | .02 |
| Hyperlipidemia | 445 (50.8) | 363 (52.3) | 51 (45.9) | 23 (47.9) | 8 (34.8) | .24 |
| Antihypertensive medication | 471 (53.8) | 372 (53.7) | 69 (62.2) | 22 (45.8) | 8 (34.8) | .05 |
| Lipid-lowering medication | 393 (44.9) | 319 (46.0) | 49 (44.1) | 19 (39.6) | 6 (26.1) | .24 |
| Antiplatelet medication | 322 (36.8) | 259 (37.3) | 39 (35.1) | 17 (35.4) | 7 (30.4) | .88 |
| Endotracheal mechanical ventilation | 59 (6.7) | 44 (6.3) | 6 (5.4) | 8 (16.7) | 1 (4.4) | .07 |
| History of DVT/PE | 99 (11.3) | 84 (12.7) | 10 (9.6) | 4 (8.3) | 1 (4.8) | .612 |
| Diagnosis of thrombophilia | 9 (1.0) | 8 (1.2) | 1 (0.9) | 0 (0) | 0 (0) | 1.00 |
| Active history of cancer | 110 (12.6) | 95 (13.7) | 12 (10.8) | 3 (6.3) | 0 (0) | .10 |
| Body mass index, kg/m2 | 29.2 (24.9-34.3) | 29.3 (24.9-33.6) | 32.3 (26.3-38.3) | 26.6 (23.6-29.7) | 28.4 (25.8-32.2) | .002 |
| White blood cell count,a 109/L | 6.8 (4.9-9.7) | 6.80 (4.90-9.80) | 6.30 (4.50-9.40) | 6.70 (5.05-8.00) | 9.20 (5.15-10.8) | .389 |
| Hemoglobin, g/dL | 13.0 (11.4-14.4) | 13.1 (11.5-14.5) | 12.3 (10.1-13.4) | 13.4 (12.0-14.9) | 12.6 (10.9-13.6) | <.001 |
| Hematocrit, % | 39.3 (34.9-43.2) | 39.4 (35.4-43.2) | 38.2 (32.3-41.9) | 41.0 (37.4-45.4) | 38.6 (32.8-41.40) | .007 |
| Platelets,b 109/L | 194 (146-250) | 190 (143-248) | 209 (158-257) | 206 (164-252) | 200 (146-280) | .15 |
| Albumin, g/dL | 3.6 (3.3-3.9) | 3.60 (3.30-3.90) | 3.60 (3.25-3.80) | 3.70 (3.40-3.90) | 3.60 (3.15-3.90) | .50 |
| Prothrombin time, seconds | 13.2 (12.2-14.5) | 13.3 (12.3-14.8) | 13.2 (12.1-14.3) | 12.9 (12.0-13.8) | 12.9 (12.1-14.2) | .15 |
| International normalized ratio | 1.2 (1.1-1.3) | 1.20 (1.10-1.30) | 1.20 (1.10-1.30) | 1.10 (1.10-1.20) | 1.15 (1.10-1.30) | .23 |
| D-dimer,c ng/mL | ||||||
| All patients | 811 (524-1453) | 796 (513-1413) | 1031 (579-1988) | 722 (479-1030) | 895 (527-1794) | .03 |
| Patients without DVT/PE | 787 (505-1331) | 782 (495-1322) | 838 (554-1399) | 638 (448-1001) | 844 (516-1630) | .22 |
| C-reactive protein, mg/L | 58.8 (23.9-112.i) | 59.9 (21.7-110) | 52.5 (26.6-114) | 76.0 (35.0-119) | 46.3 (29.7-118) | .861 |
| Pro-brain natriuretic peptide, pg/mL | 374.5 (105-1403) | 391 (116-1326) | 249 (45.0-1914) | 216 (65.0-491) | 1242 (166-7430) | .132 |
| Interleukin-6, pg/mL | 21 (9.3-46.3) | 22.0 (10.0-48.2) | 20.0 (5.80-33.0) | 18.0 (9.38-47.8) | 10.8 (6.45-30.0) | .341 |
| Procalcitonin, ng/mL | 0.14 (0.09-0.3) | 0.13 (0.09-0.29) | 0.15 (0.08-0.40) | 0.18 (0.11-0.28) | 0.19 (0.13-0.44) | .168 |
| Interval from admission to diagnosis of DVT/PE, days | 5.9 ± 10.2 | 5.9 ± 10.6 | 6.6 ± 10.5 | 1.0 ± 1.7 | 15 | .573 |
DVT, Deep vein thrombosis; PE, pulmonary embolism.
Data presented as number (%), median (interquartile range), or mean ± standard deviation.
a
Normal range: 3.4-9.6 × 109/L.
b
Normal range: 135-317 × 109/L.
c
Normal range: ≤500 mg/mL.